达维塔保健今日盘中股价大幅上涨22.55%，成为市场关注的焦点。
消息面上，该公司公布了远超市场预期的2026年第一季度财务业绩，并基于肾透析服务需求的强劲与稳定增长，上调了全年调整后利润预期。具体而言，公司第一季度调整后每股收益为2.87美元，大幅高于分析师普遍预期的2.32美元；季度营收达到34.2亿美元，也超出了33.6亿美元的市场预期。同时，公司将2026年全年经调整后每股收益预期区间上调至14.10美元至15.20美元，高于此前13.60美元至15.00美元的指引。
分析指出，这份强劲的财报显示公司在应对运营成本挑战后，业务已重拾增长势头，管理层对全年前景的乐观判断显著提振了投资者信心，是推动股价强势拉升的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.